News Releases

Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.

Site search

2020

December 17, 2020

Taiho Pharmaceutical Concludes Licensing of Automated PDPS Platform with PeptiDream
November 12, 2020

Taiho and Lung Therapeutics Enter into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions（PDF：133.0 KB）
October 16, 2020

Taiho Pharmaceutical Supports Employees' Efforts to Quit Smoking
September 30, 2020

Otsuka Group Acquires ISO 14001 Certification
-Reinforcement of group-wide environmental initiatives-（PDF：336.7 KB）
September 24, 2020

Taiho Pharmaceutical and MD Anderson announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs（PDF：35.5 KB）
September 04, 2020

Taiho Pharmaceutical Adds New Orange and Lychee Flavors to the Pitas Throat Troche Lineup
September 01, 2020

Taiho Pharmaceutical Adopts Carbon-Neutral Electricity
Annual CO₂ Emissions to Decline by Approximately 13% in the Tsukuba Area（PDF：98.9 KB）
July 28, 2020

Taiho Pharmaceutical Launches Anticancer Agent LONSURF^® (brand name in Japan) in China for Treatment of Colorectal Cancer
July 08, 2020

Taiho announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI^®, an oral hypomethylating agent (HMA) therapy for MDS and CMML（PDF：514.9 KB）
June 15, 2020

Taiho Pharmaceutical Submits Application for Additional Dosage and Administration of 5-HT₃ Receptor Antagonist　Aloxi_® for Pediatric Patients in Japan
February 27, 2020

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-PD-1 Antibody in Asia
January 06, 2020

Taiho, Astex and MSD Establish Strategic Oncology Collaboration

News Releases

Select year from the Back Number